CRL vs TGTX · rev $4.02B vs P/E 18, rev $240.3M
Charles River Laboratories (CRL) versus TG Therapeutics Inc (TGTX) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ.
Latest reported CRL revenue for 2025-12-27 was $4.02B. Net income was -$144.3M. CRL currently screens at market cap $7.78B.
Latest reported TGTX revenue for 2026-06-30 was $240.3M. Net income was $7.8M. Revenue was up 17.3% from 2026-03-31 to 2026-06-30. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
CRL currently screens at market cap $7.78B. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
Not investment advice. Open the CRL and TGTX stock pages for the full models.
Not investment advice.